DPI-221

From WikiMD's Medical Encyclopedia

Revision as of 06:44, 20 May 2024 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

DPI-221 is a synthetic opioid drug that acts as a highly selective agonist for the δ-opioid receptor. It was developed for its potential use in treating conditions such as pain, depression, and anxiety.

Pharmacology[edit]

DPI-221 is known for its high selectivity towards the δ-opioid receptor, which distinguishes it from other opioids that typically target the μ-opioid receptor. This selectivity is significant because δ-opioid receptor agonists are believed to produce fewer side effects compared to μ-opioid receptor agonists, such as reduced risk of respiratory depression and addiction.

Mechanism of Action[edit]

DPI-221 binds to and activates the δ-opioid receptor, which is a G protein-coupled receptor (GPCR). Activation of this receptor leads to a cascade of intracellular events that result in the modulation of neurotransmitter release and ultimately produce analgesic and mood-enhancing effects.

Potential Therapeutic Uses[edit]

Pain Management[edit]

Due to its analgesic properties, DPI-221 has been studied for its potential use in managing various types of pain, including chronic pain and neuropathic pain. Its selective action on the δ-opioid receptor may offer pain relief with a lower risk of side effects commonly associated with traditional opioids.

Depression and Anxiety[edit]

Research has indicated that δ-opioid receptor agonists like DPI-221 may have antidepressant and anxiolytic effects. This makes DPI-221 a candidate for the treatment of major depressive disorder and generalized anxiety disorder.

Side Effects and Safety[edit]

While DPI-221 is designed to minimize the side effects associated with traditional opioids, it is not entirely free from adverse effects. Common side effects may include nausea, dizziness, and headache. Long-term safety and efficacy studies are required to fully understand the risk profile of DPI-221.

Research and Development[edit]

DPI-221 is still under investigation, and its clinical applications are yet to be fully realized. Ongoing research aims to better understand its pharmacokinetics, pharmacodynamics, and potential therapeutic benefits.

See Also[edit]

References[edit]


Stub icon
   This article is a medical stub. You can help WikiMD by expanding it!



Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.